BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33159365)

  • 1. A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia.
    Canaani J; Danylesko I; Shemtov N; Zlotnick M; Lozinsky K; Benjamini O; Yerushalmi R; Nagar M; Dor C; Shimoni A; Avigdor A; Nagler A
    Eur J Haematol; 2021 Feb; 106(2):260-266. PubMed ID: 33159365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisantrene in relapsed and refractory acute myelogenous leukemia.
    Spadea A; Petti MC; Aloespiriti MA; Avvisati G; De Gregoris C; Fazi P; Latagliata R; Amadori S; Mandelli F
    Leuk Lymphoma; 1993 Feb; 9(3):217-20. PubMed ID: 8471980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
    Leblanc T; Deméocq F; Leverger G; Baruchel A; Lemerle S; Vannier JP; Nelken B; Guillot T; Schaison G
    Med Pediatr Oncol; 1994; 22(2):119-24. PubMed ID: 8259097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
    Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
    Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dactinomycin in acute myeloid leukemia with NPM1 mutations.
    Beziat G; Tavitian S; Bertoli S; Huguet F; Largeaud L; Luquet I; Vergez F; Rieu JB; Bories P; Delabesse E; Récher C
    Eur J Haematol; 2020 Sep; 105(3):302-307. PubMed ID: 32452083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.
    Stratmann J; van Kann E; Rummelt C; Koschade S; Röllig C; Lübbert M; Schaich M; Parmentier S; Sebastian M; Chromik J; Becker von Rose A; Ballo O; Steffen B; Serve H; Brandts C; Shaid S
    Leuk Res; 2019 Oct; 85():106192. PubMed ID: 31445469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study.
    Mills GM; Dahlberg S; Cowan J; Neilan BA; Gumbart CH; Hussein K; Coltman CA
    Am J Clin Oncol; 1989 Dec; 12(6):507-10. PubMed ID: 2589232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience.
    Carceller F; Hirsch SG; Khabra K; Petterson T; Malik R; Guerra-García P; Moreno L; Marshall LV; Taj M; Atra A; Ethell M; Potter M; Lancaster D
    Leuk Res; 2019 Oct; 85():106217. PubMed ID: 31493701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
    Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK
    Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
    Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
    Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
    N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
    Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
    Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
    J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
    Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.